Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.
PET scanning metrics after CAR T-cell therapy strongly predict survival in lymphoma, offering practical markers to guide patient monitoring.
In 212 R/R DLBCL patients from the French DESCAR-T registry, standardized FDG-PET interpretation using TMTV and Deauville scoring demonstrated that baseline TMTV >30 cm³ and metabolic response at 1 and 3 months post-CAR T-cell infusion are strong independent prognostic biomarkers for both progression-free and overall survival. These findings establish actionable PET biomarker thresholds to guide post-CAR T-cell monitoring and risk stratification in clinical practice.
What the study was
- Study design
- Retrospective registry cohort
- Population
- 212 R/R DLBCL patients from the French DESCAR-T registry treated with commercial anti-CD19 CAR T-cells in ≥3rd line
- Sample size
- 212
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
Why it surfaced
Large real-world registry (212 patients) providing standardized PET biomarker thresholds ready for clinical implementation in CAR T-cell monitoring for DLBCL; addresses current variability in response assessment standards.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.